Prevalence of and Risk Factors for Hepatic Steatosis and Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes:the Edinburgh Type 2 Diabetes Study
| Autor: | Rachel M. Williamson, G I Johnston, Lisa D. Nee, Elisa Perry, Peter C. Hayes, Jackie F. Price, Liesbeth A.F. Van Look, S Glancy, Rebecca M. Reynolds, Mark W. J. Strachan, Brian M. Frier |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2011 |
| Předmět: |
Male
medicine.medical_specialty Endocrinology Diabetes and Metabolism Population 030209 endocrinology & metabolism Type 2 diabetes Gastroenterology 03 medical and health sciences Liver disease 0302 clinical medicine Non-alcoholic Fatty Liver Disease Risk Factors Internal medicine Diabetes mellitus Nonalcoholic fatty liver disease medicine Internal Medicine Humans Advanced and Specialised Nursing Epidemiology/Health Services Research education Original Research Aged Advanced and Specialized Nursing education.field_of_study business.industry Fatty liver Middle Aged medicine.disease 3. Good health Fatty Liver Endocrinology Diabetes Mellitus Type 2 Female 030211 gastroenterology & hepatology Steatosis Metabolic syndrome business |
| Zdroj: | Williamson, R M, Price, J F, Glancy, S, Perry, E, Nee, L D, Hayes, P C, Frier, B M, Van Look, L A F, Johnston, G I & Reynolds, R M & Strachan, M 2011, ' Prevalence of and Risk Factors for Hepatic Steatosis and Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes : the Edinburgh Type 2 Diabetes Study ', Diabetes Care, vol. 34, no. 5, pp. 1139-1144 . https://doi.org/10.2337/dc10-2229 Diabetes Care |
| DOI: | 10.2337/dc10-2229 |
| Popis: | OBJECTIVE Type 2 diabetes is an established risk factor for development of hepatic steatosis and nonalcoholic fatty liver disease (NAFLD). We aimed to determine the prevalence and clinical correlates of these conditions in a large cohort of people with type 2 diabetes. RESEARCH DESIGN AND METHODS A total of 939 participants, aged 61–76 years, from the Edinburgh Type 2 Diabetes Study (ET2DS)—a large, randomly selected population of people with type 2 diabetes—underwent liver ultrasonography. Ultrasound gradings of steatosis were compared with magnetic resonance spectroscopy in a subgroup. NAFLD was defined as hepatic steatosis in the absence of a secondary cause (screened by questionnaire assessing alcohol and hepatotoxic medication use, plasma hepatitis serology, autoantibodies and ferritin, and record linkage to determine prior diagnoses of liver disease). Binary logistic regression was used to analyze independent associations of characteristics with NAFLD. RESULTS Hepatic steatosis was present in 56.9% of participants. After excluding those with a secondary cause for steatosis, the prevalence of NAFLD in the study population was 42.6%. Independent predictors of NAFLD were BMI, lesser duration of diabetes, HbA1c, triglycerides, and metformin use. These remained unchanged after exclusion of participants with evidence of hepatic fibrosis from the group with no hepatic steatosis. CONCLUSIONS Prevalences of hepatic steatosis and NAFLD were high in this unselected population of older people with type 2 diabetes, but lower than in studies in which ultrasound gradings were not compared with a gold standard. Associations with features of the metabolic syndrome could be used to target screening for this condition. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|